<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is a <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> with ocular, musculoskeletal and cardiovascular manifestations that are caused by mutations in fibrillin-1, the major constituent of extracellular microfibrils </plain></SENT>
<SENT sid="1" pm="."><plain>Mouse models of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> have revealed that fibrillin-1 mutations perturb local TGFbeta signaling, in addition to impairing tissue integrity </plain></SENT>
<SENT sid="2" pm="."><plain>This discovery has led to the identification of a new syndrome with overlapping <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>-like manifestations that is caused by mutations in TGFbeta receptor types I and II </plain></SENT>
<SENT sid="3" pm="."><plain>It has also prompted the idea that TGFbeta antagonism will be a productive treatment strategy in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> and perhaps in other related disorders </plain></SENT>
<SENT sid="4" pm="."><plain>More generally, these studies have established that <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is part of a group of <z:e sem="disease" ids="C0008073" disease_type="Mental or Behavioral Dysfunction" abbrv="">developmental disorders</z:e> with broad and complex effects on morphogenesis, homeostasis and organ function </plain></SENT>
</text></document>